Indication
Tinea pedis, Tinea cruris, Tinea corporis, Dermatophytosis, Nail infections, Cutaneous candidiasis, Pityriasis versicolor
Adult Dose
Topical/Cutaneous As cream or spray Dermatophytosis Adult: Tinea Pedis: Apply to affected area BID until significant clinical improvement (no more than 4 weeks) Tinea Corporis & Cruris: Apply once daily, for 1 week, (no more than 4 weeks) Cutaneous candidiasis and pityriasis versicolor: Apply once or bid for 2 wk
Child Dose
Not FDA approved for peds
Contraindication
Hypersensitivity, active or chronic liver disease, lactation.
Mode of Action
Terbinafine causes fungal cell death by inhibiting squalene epoxidase, the main enzyme in sterol biosynthesis, resulting in ergosterol deficiency within fungal cell walls. It has fungicidal activity against dermatophytes and some yeast.
Precaution
Preexisting liver or renal impairment, pregnancy. Perform liver function tests prior to oral therapy. Lactation: not safe for nursing infants
Side Effect
1-10% Burning,Contact dermatitis,Dryness,Exfoliation,Irritation,Pruritus,Rash,Irritation,Stinging Potentially Fatal: Liver failure, Stevens-Johnson syndrome, neutropaenia.
Interaction
Possible increase in levels in drugs metabolised by CYP450 2D6. Decreased terbinafine concentration with rifampicin; increased terbinafine concentration with cimetidine.

















